# A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

> **NCT04786028** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Myeloma Research Group** · enrollment: 72 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** Isatuximab

## Key facts

- **NCT ID:** NCT04786028
- **Lead sponsor:** Canadian Myeloma Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-08
- **Primary completion:** 2026-03
- **Final completion:** 2027-06
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04786028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04786028, "A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04786028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*